Journey Medical Corp
DERM Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$5.02
KIRA · Stoqly’s AI analyst, in plain words
- Journey Medical Corp had $61.9M of revenue in fiscal 2025, up 10.2% on the year before. Over five years, revenue changed +6.8% a year on average.
- Its operating margin was −13.2%, up 11.2 pts: of every 100 in sales, about −13 is left after running the business.
- Journey Medical Corp lost $11.4M in fiscal 2025.
- Journey Medical Corp owes $1.2M more than it holds in cash.
Market cap
$138M
P/E
—
Revenue
$61.9M
Net income
−$11.4M
Free cash flow
—
Operating margin
−13.2%
Journey Medical Corp in 30 seconds · fiscal 2025
Are sales growing?
+10.2%
Yes. Sales grew 10.2% last year.
Does it make a profit?
−18.5%
No. It lost money last year.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Journey Medical Corp does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 26, 2026
- Legal name
- Journey Medical Corp
- CIK
- 0001867066
Journey Medical Corp · DERM
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $63.1M | $73.7M | $79.2M | $56.1M | $61.9M |
| Revenue growth | 41.8% | 16.7% | 7.5% | −29.1% | 10.2% |
| Gross margin | 49.2% | 58.2% | 71.1% | 62.8% | 66.2% |
| Operating margin | −55.2% | −37.4% | −2.6% | −24.4% | −13.2% |
| Net income | −$44.0M | −$29.6M | −$3.9M | −$14.7M | −$11.4M |
| Net margin | −69.7% | −40.2% | −4.9% | −26.1% | −18.5% |
| Diluted EPS | −$4.32 | −$1.69 | −$0.21 | −$0.72 | −$0.47 |
| Cash | |||||
| Cash from operations | −$2.2M | −$13.5M | $5.2M | −$9.1M | −$12.4M |
| Capital expenditure | — | $20.0M | $5.0M | $15.0M | — |
| Free cash flow | — | −$33.5M | $0.2M | −$24.1M | — |
| FCF margin | — | −45.5% | 0.3% | −43.0% | — |
| Share count change | −6.0% | 72.0% | 4.0% | 12.1% | 19.9% |
| Debt and strength | |||||
| Cash and short-term investments | $49.1M | $32.0M | $27.4M | $20.3M | $24.1M |
| Debt incl. finance leases | — | $27.8M | $14.6M | $24.9M | $25.3M |
| Shareholders' equity | $42.0M | $17.0M | $20.4M | $20.1M | $31.9M |
| Current ratio | 1.6x | 1.2x | 1.3x | 1.4x | 1.8x |
| Interest coverage | −5.0x | −13.6x | −1.2x | −5.1x | −2.2x |
| Returns and quality | |||||
| Return on capital | — | −170.6% | −21.7% | −43.8% | −19.5% |
| Return on equity | −168.1% | −100.4% | −20.6% | −72.6% | −44.0% |
| Return on tangible equity | −149.2% | — | −6,115.9% | — | −269.2% |
| Piotroski F-score | 3 | 4 | 7 | 2 | 4 |
| Altman Z'' | −0.7 | −3.0 | −1.6 | −3.3 | −1.4 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Journey Medical Corp · DERM
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $5.02 a share, the company is worth $138M.
Source: SEC EDGAR XBRL filings (CIK 0001867066). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.